Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
haha yup, nothing available on the bid, going to need to slap the ask
Nice slaps working on that wall..someone is about to loose their shares!
Does anyone have a screenshot of level two from yesterday here? I don’t remember seeing these large bidders lurking like this at .015 and .013 .
That’s got to be the reason that’s up there, when he’s done watch out because this is going to takeoff!
someone has up a loading wall, might be a good place to load up with the big boys
Codebase Investment Adds Oral Mucosal Patent Filing, Expanding Transdermal Treatments
https://www.otcmarkets.com/stock/BKLLF/news/story?e&id=1582653
NEWS
Codebase Investment Adds Oral Mucosal Patent Filing, Expanding Transdermal Treatments
New US Provisional Patent Filing for Novel Oral Drug Delivery of Chloroquine and/or Hydroxychloroquine Complements Transdermal Patch for drug used globally for Malaria, Lupus and Rheumatoid Arthritis
VANCOUVER, BC / ACCESSWIRE / April 23, 2020 / Codebase Ventures Inc. ("Codebase" or the "Company") (CSE:CODE)(FSE:C5B)(OTCQB:BKLLF), an investment company, is excited to expand on its announcement on April 16th, 2020, as it relates to a new delivery mechanism for decades old drug used to treat malaria, lupus and rheumatoid arthritis.
Adding to the previously announced provisional patent filing for a transdermal patch delivery of hydroxychloroquine, the private company with which Codebase has entered into an arms-length agreement to acquire a 49% interest, Glanis Pharmaceuticals Inc, has filed for an additional US provisional patent for the novel oral drug delivery of hydroxychloroquine (HCQ) and chloroquine (CQ).
"With the previously announced transdermal patch filing, and now this novel oral delivery filing, steps are advancing quickly to satisfy a need for an improved drug delivery system of CQ and HCQ, which can replace the multiple dosage regimen associated with oral tablets and also decrease the probabilities of getting side effects related to GI tract disturbance," said Codebase President and CEO, Mr. George Tsafalas.
CODE has agreed to acquire a 49% interest in a private company that has secured the rights to the recently applied provisional patent application for a novel oral drug delivery system for hydroxychloroquine (HCQ), in addition to the previously announced transdermal patch provisional patent filing.
This transformative delivery system will initially seek approval through the FDA 505(b)(2) accelerated pathway provisions.
These new drug delivery systems could potentially provide an innovation for those long-term patients suffering from malaria, lupus and rheumatoid arthritis who have depended on HCQ for decades and have had to accept the side effects related to oral tablet delivery.
While there has been widespread publicity concerning HCQ as a treatment for Covid-19, there has been no recognized drug trial results to date.
In oral mucosal drug delivery, an oral mucosal patch or orally disintegrating composition is applied to the mucosal surface of the oral cavity. Throughout the duration of the application of an oral mucosal patch or oral disintegrating composition, the drug is continuously released and delivered through the intact mucosa to achieve systemic effect. Therefore, once applied, oral disintegrating composition or oral mucosal method can deliver drug into systemic circulation throughout the day. Currently, RRL has started evaluating the possibility of delivering HCQ for more than one day using their novel oral drug delivery system.
Oral mucosal delivery can reduce the dosing frequency of chloroquine (CQ) and hydroxychloroquine (HCQ) which is currently administered orally 2-3 times a day. Moreover, in oral mucosal drug delivery, the drug is delivered slowly and continuously throughout the duration of oral application hence there are no peaks and troughs in drug plasma concentration which are associated with multiple dose administration in a day. With respect to CQ and HCQ, it is expected that adverse effects in patients will be less with the oral mucosal delivery as drug plasma concentration with oral mucosal delivery is less than peak plasma concentration associated with oral tablets.
As consideration for this additional provisional patent and on-going work, the Company will issue up to 6 million common shares and pay $20,000 USD pursuant to a lab services agreement with a New York based laboratory, Reformulation Research Laboratories Inc. (RRL), that developed the patent application and the underlying technology. These shares will be issued at a deemed price of $0.05 per share. The agreement is subject to closing conditions usually found in transactions of this kind.
While hydroxychloroquine is the subject of various early studies of its effectiveness against the Covid-19, its present on-label uses as a treatment against malaria, lupus and rheumatoid arthritis provides a ready market for this proposed new delivery system. This new delivery method can eliminate or reduce a number of the common side effects of this treatment, including nausea, vomiting, loss of appetite, diarrhea, dizziness, or headache by providing a controlled constant delivery.
RRL has a combined 75 years of expertise in novel drug delivery systems that provide the capacity, equipment and capabilities to advance the development program for a hydroxychloroquine molecule for oral mucosal delivery from research, testing, regulatory approvals through to launch of the hydroxychloroquine oral mucosal delivery system.
The Company's scientific expert has read and approved the scientific disclosures contained in the press release. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the Covid-19 at this time. RRL is not making any express or implied claims that any of its products have the ability to deliver hydroxychloroquine through transdermal/oral at this time.
About Codebase Ventures Inc.
Codebase Ventures Inc. is a diversified investment company, led by technology, biotechnology and business experts who invest early in great ideas in sectors that have significant upside, including the cannabis sector. We operate from the understanding that technology is always evolving, bringing early opportunities for strategic investments that can deliver the exponential returns to our shareholders. We seek out and empower the innovators who are building tomorrow's standards with platforms, protocols and innovations - not just products. We invest early, support those founders, take their ideas to market and work tirelessly to help them realize their vision.
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
For further information, please contact:
George Tsafalas - Ivy Lu
Investor Relations
Telephone: Toll-Free (877) 806-CODE (2633) or 1 (778) 806-5150
E-mail: IR@codebase.ventures
www.codebase.ventures.com
Forward Looking Statements
Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. All statements other than statements of historical fact are forward-looking statements, including, without limitation, statements regarding future financial position, business strategy, use of proceeds, corporate vision, proposed acquisitions, partnerships, joint-ventures and strategic alliances and co-operations, budgets, cost and plans and objectives of or involving the Company. Such forward-looking information reflects management's current beliefs and is based on information currently available to management. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "predicts", "intends", "targets", "aims", "anticipates" or "believes" or variations (including negative variations) of such words and phrases or may be identified by statements to the effect that certain actions "may", "could", "should", "would", "might" or "will" be taken, occur or be achieved. A number of known and unknown risks, uncertainties and other factors may cause the actual results or performance to materially differ from any future results or performance expressed or implied by the forward-looking information. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company including, but not limited to, the successful development of a transdermal patch, the successful results of trials, other competing products, the impact of general economic conditions, industry conditions and dependence upon regulatory approvals. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company does not assume any obligation to update or revise its forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by securities laws.
SOURCE: Codebase Ventures Inc.
View source version on accesswire.com:
https://www.accesswire.com/586422/Codebase-Investment-Adds-Oral-Mucosal-Patent-Filing-Expanding-Transdermal-Treatments
© Copyright 2020 ACCESSWIRE. All Rights Reserved.
Back to News Headlines
Other Financial Information
Recent News & Disclosure Filings
Recent SEC Filings
OTCQB Member Since 02/2019
OTCQB
OTCQB Venture
Verified Profile 01/2020
Nice green start here..looks to climb from here...
just need to tighten up that spread and we'll be good to push over .02
market cap is small here - with all the big news hitting recently this seems very undervalued
$bkllf..ask moving higher..looks like news is making its way around!
this chart looks set up to bounce off support
https://twitter.com/Ridefixer4u/status/1253282848527847425
wow nice news out for $BKLLF!
https://www.otcmarkets.com/stock/BKLLF/news/story?e&id=1582653
Impressive that $bkllf is listed on the Canadian stock exchange as well..$code
Looks like this company is working hard! More news! https://finance.yahoo.com/news/codebase-investment-adds-oral-mucosal-070100461.html
https://twitter.com/autumnsdad1/status/1253281786622365696?s=20
$bkllf #code news starting to get around twitter..these cheap shares look to go fast this morning..
Nice cheap shares loaded today..smart traders got a gift..should be trading much higher $bkllf $code
Back on the bottom of the trading channel here at .022. Good buy point
VANCOUVER, BC, CANADA (April 21st, 2020) – Codebase Ventures Inc.
VANCOUVER, BC, CANADA (April 21st, 2020) – Codebase Ventures Inc. ("Codebase" or the
"Company") (CSE: CODE - FSE: C5B – OTCQB: BKLLF), an investment company, is pleased to
expand upon its announcement of April 16th regarding its agreement to acquire a 49% interest in
an arms-length private company with the rights to a provisional patent for a transdermal drug
delivery system for hydroxychloroquine (HCQ) to treat malaria, lupus and rheumatoid arthritis.
Hydroxychloroquine has been heavily publicized in relation to its potential treatment and
prevention role with Covid-19, leading to instances of self medication, where
“hydroxychloroquine can have dangerous side-effects if the dose is not carefully controlled.”1,2
• In oral tablet form, hydroxychloroquine side effects include headache, dizziness, diarrhea,
vomiting, blurred vision, and arrhythmia among others3
• Transdermal delivery of hydroxychloroquine regulates dosage, improving patient
compliance and outcomes4
• Bypassing the GI tract mitigates gastrointestinal side effects
• Transdermal delivery is more efficient, therefore requiring less of the active ingredient to
be administered
The hydroxychloroquine transdermal drug delivery system to be developed by an investee
company of Codebase is designed to control dosage and to deliver the prescribed amount of
the drug over the prescribed time period without inconsistencies inherent in oral tablet delivery
- the premise being that transdermal delivery can reduce and/or eliminate side effects
associated with uncontrolled dosing.
Reformulation Research Laboratories Inc. (RRL), Code’s contract lab partners in the venture,
have provided that transdermal delivery of hydroxychloroquine can result in improved well
being for patients by providing constant drug levels, fewer side effects overall, highlighted by
the fact unlike oral tablets, transdermal delivery bypasses the gastrointestinal tract which can
eliminate side effects from that route such as nausea. In addition, limitations on bioavailability
and metabolism of the active ingredient when taken orally require dosages to be higher than
what is required for therapeutic results. Transdermal delivery is more efficient, and with
2
greater bioavailability and therefore lower amounts of the active ingredient are required, which
also can improve outcomes for patients.
The Company’s scientific expert has read and approved the scientific disclosures contained in the
press release. The Company is not making any express or implied claims that its product has the
ability to eliminate, cure or contain the Covid-19 at this time. RRL is not making any express or
implied claims that any of its products have the ability to deliver hydroxychloroquine through
transdermal at this time.
1 https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30089-8/fulltext
2 https://nationalpost.com/news/politics/canada-quietly-secured-order-for-5-millions-pills-of-anti-malariamedication-eyed-as-potential-covid-19-treatment
3 https://www.healthline.com/health/hydroxychloroquine-oral-tablet
4 https://www.sciencedirect.com/topics/medicine-and-dentistry/transdermal-drug-administration
Good morning, I really like how this trades!
Hydroxychloroquine Treatment for COVID-19 Benefits Sought in Global Research Effort to Establish Efficacy
Links:
4-21-20
https://www.otcmarkets.com/stock/BKLLF/news/story?e&id=1580237
4-20-20
https://www.otcmarkets.com/stock/BKLLF/news/story?e&id=1579595
GLTA!
Very nice updates Palo, Sitback,Relax, Ka-Booom!
Thank you for the updates Palo, the EU markets showing 15% already.
its going to be an interesting day.
GLTA!
Codebase Investee has secured rights to develop a Transdermal Hydroxychloroquine Drug Delivery System to offer controlled, prescribed dosage mitigating side effects
VANCOUVER, BC / ACCESSWIRE / April 21, 2020 / Codebase Ventures Inc. ("Codebase" or the "Company") (CSE:CODE)(FSE:C5B)(OTCQB:BKLLF), an investment company, is pleased to expand upon its announcement of April 16th regarding its agreement to acquire a 49% interest in an arms-length private company with the rights to a provisional patent for a transdermal drug delivery system for hydroxychloroquine (HCQ) to treat malaria, lupus and rheumatoid arthritis.
https://markets.businessinsider.com/news/stocks/hydroxychloroquine-side-effects-potentially-mitigated-by-transdermal-delivery-1029110862
Got some BKLLF and TAUG today.
Bio sciences are super right now.
https://finance.yahoo.com/news/hydroxychloroquine-treatment-covid-19-benefits-133000513.html
HOT!......
https://www.otcmarkets.com/stock/TAUG/news/Aegea-Biotechnologies-Inc-Expands-its-Platforms-for-Novel-Coronavirus-COVID-19-Testing-under-the-Collaboration-Agreement?id=259587
GLTA!
$bkllf huge buying volume today will be steering off radars tonight..$code
just cleared 1M in volume! great looking day
Excellent point homeboy..
I forget that this also trades in Canada (CSE) under ticker symbol CODE
check out those large bids stacking now!
$BKLLF ask rocking now, looks like .025 about to fall
$CODE
$bkllf $code buying volume pouring in now!!!
$bkllf $code .024 just got crushed!! .0255 up and thin!
Check out this chart when you get a chance because there’s a channel that you can trade this one in and make great money!
https://twitter.com/ridefixer4u/status/1252269024337068032?s=21
Beautiful treating channel on this one! https://investorshub.advfn.com/uimage/uploads/2020/4/20/inrgdECE3B3DE-96EA-4F79-98B0-49D7AB51561E.jpeg">https://investorshub.advfn.com/uimage/uploads/2020/4/20/inrgdECE3B3DE-96EA-4F79-98B0-49D7AB51561E.jpeg" />
$bkllf strong buys continues to take out loading wall..very close to strong breakout here..
$bkllf looks like someone is taking an ax to the ask!
grabbed a few here, .025's just about gone!
L2 looks rock solid! I don’t see fake bids just solid ones!
Strong ask slaps taking out .025 quickly here!
spread is tightening up, might have to slap the ask soon
This is big new for those of us that fear needles!
https://finance.yahoo.com/news/codebase-invest-company-developing-hydroxychloroquine-070100939.html
$bkllf that news just hit my feed now after the market opened..I must read..no wonder it jumped out of the gate!
this could be huge
Codebase Ventures Inc. ("Codebase" or the "Company") (CSE:CODE)(FSE:C5B)(OTCQB:BKLLF), an investment company, is pleased to build upon its announcement of April 16th regarding its binding letter of intent to invest in an arms-length private company with rights to a provisional patent for a transdermal drug delivery system for hydroxychloroquine (HCQ), a drug currently used to treat malaria, lupus and rheumatoid arthritis, and being tested as a potential treatment for COVID-19. Hydroxychloroquine is now being tested on a global basis for the treatment and prevention of COVID-19, highlights include:
World Health Organization launches Solidarity clinical trial now in 90 countries on treatment efficacy
UK wide randomized, controlled trial in over 130 hospitals called Recovery is underway
NYU and University of Washington fast track major clinical trial to determine role of HCQ in prevention of coronavirus
looks like a loading wall at .026, will try to nibble on the bid for now
Covid news caught my eye today
https://www.otcmarkets.com/stock/bkllf/news/story?e&id=1579595
BKLLF...0242...Hod on the 200ma break...
Followers
|
23
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
309
|
Created
|
10/20/17
|
Type
|
Free
|
Moderators |
Shares: 126,693,061
Warrants: 40,138,490
Stock Options: 10,350,000
Total Shares Outstanding (Fully Diluted): 177,181,551
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |